PUBLICATION
India Pharmaceuticals 2017 Pre-Release
India’s pharmaceutical industry, ranked third worldwide in terms of volume, is the largest supplier of generic drugs globally and a proponent of high-quality affordable medicines. The industry has posted double-digit growth over the last few years, rising to US$36.7 billion and projected to grow to US$40 billion by 2020. However, as price erosion continues to impact the market and competition increases, many of India’s pharmaceutical companies will be hard-pressed to continue pushing products into the market at ever-more affordable prices. A number of policies under discussion, outlined in the Draft Pharmaceutical Policy 2017, seek to address the challenges faced by Indian pharmaceutical companies. Implementation and open dialogue between government and industry will be key in ensuring its success.
RELATED INTERVIEWS MORE INTERVIEWS
RELATED ARTICLES MORE ARTICLES
Finding Funding: The Diversification of the Biotech Financing Landscape
A West-Meets-East Of The Pharma Industry
RECENT PUBLICATIONS
In August 2023, Mexican exports to the US surpassed China for the first time. As companies prioritize securing supply their chains after years of logistics challenges, Mexico has begun to see major benefits. With a spate of new infrastructure projects such as the Interoceanic Corridor of the Isthmus of Tehuantepec coming online in 2023, the country is actively opening itself to investment. The chemical industry, in particular, is positioned for nearshoring-driven growth.
MORE PREVIOUSLY PUBLISHED
MACIG
SUBSCRIBE TO OUR NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
